<DOC>
	<DOCNO>NCT00176826</DOCNO>
	<brief_summary>The hypothesis determine preparative regimen busulfan , cyclophosphamide , antithymocyte globulin ( ATG ) plus allogeneic stem cell transplantation effective treatment immune deficiency histiocytic disorder .</brief_summary>
	<brief_title>T-Cell Depletion Stem Cell Transplant Immune Deficiencies Histiocytic Disorders</brief_title>
	<detailed_description>Subjects begin chemotherapy preparative regimen , intend completely eliminate defective immune system bone marrow . The preparative regimen consist chemotherapy drug ( busulfan , cyclophosphamide , antithymocyte globulin ( ATG ) ) . Transplantation : subject source blood stem cell ( bone marrow ) donor administer catheter . Medication give help prevent Graft-Versus Host Disease ( GVHD ) . The ATG help deplete donor stem cell type cell cause GVHD also help promote engraftment new stem cell . Recovery Phase : The second phase treatment consist period transplantation wait return bone marrow function . This usually take two four week . Subjects give blood cell growth factor , G-CSF , help speed recovery white blood cell potentially decrease risk infection decrease time bone marrow recovers .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Histiocytosis</mesh_term>
	<mesh_term>Histiocytosis , Langerhans-Cell</mesh_term>
	<mesh_term>Lymphohistiocytosis , Hemophagocytic</mesh_term>
	<mesh_term>Chediak-Higashi Syndrome</mesh_term>
	<mesh_term>Immune System Diseases</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Any patient birth &lt; 55 year age fulfil follow criterion eligible study . Patients meet clinical diagnostic criterion Hemophagocytic Lymphohistiocytosis ( HLH ) Patients meet clinical diagnostic criterion genetic diagnosis Xlinked lymphoproliferative disorder ( XLP ) whose disease ACTIVE STABLE , NONACTIVE/QUIESCENT . Patients ChediakHigashi Syndrome meet follow diagnostic criterion whose disease ACTIVE STABLE , NONACTIVE/QUIESCENT define Appendix V study protocol . Patients Viral Associated Hemophagocytic Syndrome ( VAHS ) relapse therapy supportive care . Diagnostic criterion HLH . Disease status must ACTIVE STABLE , NONACTIVE/QUIESCENT define Appendix V. It caution many patient HLH familial hemophagocytic lymphohistiocytosis ( FHL ) viral infection time initial presentation may therefore misdiagnosed VAHS . Griscelli Syndrome Primary immune deficiency nongenotypic identical donor . Progressive Langerhans cell histiocytosis unresponsive standard therapy . Other nonmalignant hematological disorder stem cell transplant myeloablative regimen indicate . Diamond Blackfan Anemia transfusion dependent Schwachman Diamond Syndrome : cytopenia transformation myelodysplastic syndrome ( MDS ) Kostman 's Syndrome ( ANC &lt; 500 without GCSF support , transformation MDS ) Congenital dyserythropoietic anemia transfusion dependent Amegakaryocytic thrombocytopenia baseline platelet count &lt; 20,000 require transfusion . Cardiac , hepatic , renal pulmonary function deem adequate high dose chemotherapy stem cell rescue per institutional standard . General guideline follow : Cardiac : Asymptomatic , symptomatic , leave ventricular ejection fraction rest must &gt; 40 % must improve exercise , shorten fraction echocardiogram must within institutional normal Hepatic : &lt; 3 x normal SGOT &lt; 2.5 mg/dL serum bilirubin Renal : Serum creatinine within normal range , serum creatinine outside normal range creatinine clearance glomerular filtration study &gt; 50 % normal . Pulmonary : Asymptomatic , symptomatic , diffuse capacity lung carbon monoxide ( DLCO ) &gt; 45 % predict ( correct hemoglobin ) . For child unable perform pulmonary function testing , oxygen saturation &gt; 95 % . Availability suitable allogeneic bone marrow donor per current institutional guideline nonT cell deplete hematopoietic stem cell transplant ( HSCT ) . Patients undergone previous stem cell transplant ( SCT ) fail engraftment relapse disease consider eligible meet eligibility criterion second SCT would occur 6 month first . If first SCT preparative regimen nonmyeloablative intensity second SCT could perform early acute toxicity procedure resolve . Patients moribund whose life expectancy severely limited disease underlie disorder . Karnofsky performance status &lt; 70 % Lansky &lt; 50 % patient &lt; 16 year . Patients hemophagocytic disorder secondary underlying malignancy . Patients ACTIVE/UNSTABLE disease define Appendix V. Significant active infection , include Human Immunodeficiency Virus ( HIV ) . Age &gt; 55 year . Not provide inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Stem Cell Transplant</keyword>
	<keyword>T-cell depletion</keyword>
	<keyword>immune deficiency</keyword>
	<keyword>Busulfan pharmacokinetics</keyword>
	<keyword>Non-Malignant Hematological Disorders</keyword>
</DOC>